Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 27

1.

Multifocal Signal Modulation Therapy by Celecoxib: A Strategy for Managing Castration-Resistant Prostate Cancer.

Benelli R, Barboro P, Costa D, Astigiano S, Barbieri O, Capaia M, Poggi A, Ferrari N.

Int J Mol Sci. 2019 Dec 3;20(23). pii: E6091. doi: 10.3390/ijms20236091.

2.

Role of Circulating Tumor Cells (CTC), Androgen Receptor Full Length (AR-FL) and Androgen Receptor Splice Variant 7 (AR-V7) in a Prospective Cohort of Castration-Resistant Metastatic Prostate Cancer Patients.

Cattrini C, Rubagotti A, Zinoli L, Cerbone L, Zanardi E, Capaia M, Barboro P, Boccardo F.

Cancers (Basel). 2019 Sep 13;11(9). pii: E1365. doi: 10.3390/cancers11091365.

3.

A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.

Capaia M, Granata I, Guarracino M, Petretto A, Inglese E, Cattrini C, Ferrari N, Boccardo F, Barboro P.

Int J Mol Sci. 2018 Jun 30;19(7). pii: E1920. doi: 10.3390/ijms19071920.

4.

Proteomics study of silver nanoparticles on Caco-2 cells.

Gioria S, Urbán P, Hajduch M, Barboro P, Cabaleiro N, La Spina R, Chassaigne H.

Toxicol In Vitro. 2018 Aug;50:347-372. doi: 10.1016/j.tiv.2018.03.015. Epub 2018 Apr 4.

5.

Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer.

Ferrari N, Granata I, Capaia M, Piccirillo M, Guarracino MR, Venè R, Brizzolara A, Petretto A, Inglese E, Morini M, Astigiano S, Amaro AA, Boccardo F, Balbi C, Barboro P.

Cell Commun Signal. 2017 Dec 8;15(1):51. doi: 10.1186/s12964-017-0206-x.

6.

The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.

Brizzolara A, Benelli R, Venè R, Barboro P, Poggi A, Tosetti F, Ferrari N.

Cancer Lett. 2017 Aug 1;400:9-17. doi: 10.1016/j.canlet.2017.04.025. Epub 2017 Apr 25.

PMID:
28450158
7.

A combined proteomics and metabolomics approach to assess the effects of gold nanoparticles in vitro.

Gioria S, Lobo Vicente J, Barboro P, La Spina R, Tomasi G, Urbán P, Kinsner-Ovaskainen A, François R, Chassaigne H.

Nanotoxicology. 2016 Aug;10(6):736-48. doi: 10.3109/17435390.2015.1121412. Epub 2016 Feb 10.

8.

Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression.

Barboro P, Ferrari N, Capaia M, Petretto A, Salvi S, Boccardo S, Balbi C.

Int J Cancer. 2015 Oct 1;137(7):1574-86. doi: 10.1002/ijc.29531. Epub 2015 Apr 6.

9.

Emerging roles of heterogeneous nuclear ribonucleoprotein K (hnRNP K) in cancer progression.

Barboro P, Ferrari N, Balbi C.

Cancer Lett. 2014 Oct 1;352(2):152-9. doi: 10.1016/j.canlet.2014.06.019. Epub 2014 Jul 10. Review.

PMID:
25016060
10.

A proteomic approach to investigate AuNPs effects in Balb/3T3 cells.

Gioria S, Chassaigne H, Carpi D, Parracino A, Meschini S, Barboro P, Rossi F.

Toxicol Lett. 2014 Jul 15;228(2):111-26. doi: 10.1016/j.toxlet.2014.04.016. Epub 2014 Apr 26.

11.

Prostate cancer: prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression.

Barboro P, Salvi S, Rubagotti A, Boccardo S, Spina B, Truini M, Carmignani G, Introini C, Ferrari N, Boccardo F, Balbi C.

Int J Oncol. 2014 May;44(5):1589-98. doi: 10.3892/ijo.2014.2345. Epub 2014 Mar 14.

PMID:
24626777
12.

Androgen receptor activity is affected by both nuclear matrix localization and the phosphorylation status of the heterogeneous nuclear ribonucleoprotein K in anti-androgen-treated LNCaP cells.

Barboro P, Borzì L, Repaci E, Ferrari N, Balbi C.

PLoS One. 2013 Nov 13;8(11):e79212. doi: 10.1371/journal.pone.0079212. eCollection 2013.

13.

The role of nuclear matrix proteins binding to matrix attachment regions (Mars) in prostate cancer cell differentiation.

Barboro P, Repaci E, D'Arrigo C, Balbi C.

PLoS One. 2012;7(7):e40617. doi: 10.1371/journal.pone.0040617. Epub 2012 Jul 11.

14.

Prognostic value of nuclear matrix protein expression in localized prostate cancer.

Ricci F, Rubagotti A, Zinoli L, Mangerini R, Nuzzo PV, Carmignani G, Simonato A, Barboro P, Balbi C, Boccardo F.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1379-84. doi: 10.1007/s00432-012-1216-0. Epub 2012 Apr 10.

PMID:
22488172
15.

Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/β-catenin signaling in prostate cancer cells.

Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, Balbi C, Ferrari N.

Int J Cancer. 2012 Aug 1;131(3):582-90. doi: 10.1002/ijc.26402. Epub 2011 Oct 20. Erratum in: Int J Cancer. 2014 Nov 1;135(9):E9.

16.

Androgen receptor and heterogeneous nuclear ribonucleoprotein K colocalize in the nucleoplasm and are modulated by bicalutamide and 4-hydroxy-tamoxifen in prostatic cancer cell lines.

Barboro P, Repaci E, Ferrari N, Rubagotti A, Boccardo F, Balbi C.

Prostate. 2011 Sep 15;71(13):1466-79. doi: 10.1002/pros.21366. Epub 2011 Feb 14.

PMID:
21321982
17.

Organization of the lamin scaffold in the internal nuclear matrix of normal and transformed hepatocytes.

Barboro P, D'Arrigo C, Repaci E, Patrone E, Balbi C.

Exp Cell Res. 2010 Apr 1;316(6):992-1001. doi: 10.1016/j.yexcr.2009.12.010. Epub 2009 Dec 21.

PMID:
20026109
18.

Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.

Benelli R, Monteghirfo S, Balbi C, Barboro P, Ferrari N.

Int J Cancer. 2009 Jun 15;124(12):2989-96. doi: 10.1002/ijc.24305.

19.

Proteomic analysis of the nuclear matrix in the early stages of rat liver carcinogenesis: identification of differentially expressed and MAR-binding proteins.

Barboro P, D'Arrigo C, Repaci E, Bagnasco L, Orecchia P, Carnemolla B, Patrone E, Balbi C.

Exp Cell Res. 2009 Jan 15;315(2):226-39. doi: 10.1016/j.yexcr.2008.10.017. Epub 2008 Oct 28.

PMID:
19000672
20.

Differential proteomic analysis of nuclear matrix in muscle-invasive bladder cancer: potential to improve diagnosis and prognosis.

Barboro P, Rubagotti A, Orecchia P, Spina B, Truini M, Repaci E, Carmignani G, Romagnoli A, Introini C, Boccardo F, Carnemolla B, Balbi C.

Cell Oncol. 2008;30(1):13-26.

Supplemental Content

Loading ...
Support Center